BRD9 degraders as chemosensitizers in acute leukemia and multiple myeloma
Abstract Bromodomain-containing protein 9 (BRD9), an essential component of the SWI/SNF chromatin remodeling complex termed ncBAF, has been established as a therapeutic target in a subset of sarcomas and leukemias. Here, we used novel small molecule inhibitors and degraders along with RNA interferen...
Main Authors: | Ellen Weisberg, Basudev Chowdhury, Chengcheng Meng, Abigail E. Case, Wei Ni, Swati Garg, Martin Sattler, Abdel Kareem Azab, Jennifer Sun, Barbara Muz, Dana Sanchez, Anthia Toure, Richard M. Stone, Ilene Galinsky, Eric Winer, Scott Gleim, Sofia Gkountela, Alexia Kedves, Edmund Harrington, Tinya Abrams, Thomas Zoller, Andrea Vaupel, Paul Manley, Michael Faller, BoYee Chung, Xin Chen, Philipp Busenhart, Christine Stephan, Keith Calkins, Debora Bonenfant, Claudio R. Thoma, William Forrester, James D. Griffin |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2022-07-01
|
Series: | Blood Cancer Journal |
Online Access: | https://doi.org/10.1038/s41408-022-00704-7 |
Similar Items
-
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
by: Basudev Chowdhury, et al.
Published: (2024-03-01) -
BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
by: Lemin Li, et al.
Published: (2023-08-01) -
Development of chemical probes for the bromodomains of BRD7 and BRD9
by: Clark, P, et al.
Published: (2016) -
BRD3 and BRD4 BET bromodomain proteins differentially regulate skeletal myogenesis
by: Roberts, T, et al.
Published: (2017) -
Dissecting the Role of BET Bromodomain Proteins BRD2 and BRD4 in Human NK Cell Function
by: Cribbs, AP, et al.
Published: (2021)